Antoine Papiernik

In fact, it's probably about 60% of what we do.

We do medtech, and then we do digital medicine, and we do what we call industrial biotech.

That's biotech in particular for developing products using biotechnology outside of healthcare.

If you look at this, you mentioned over 100 companies.

I think it's 110 at today's count.

In the 60s, our pure biotech, biopharma addressing major drugs, addressing major unmet clinical need.

We have about 25%, 20% of medical device from early incubation to middle stage to commercial stage.

And then we have a growing digital medicine.

I'm sure you're going to ask me the AI question at some point.

And I'll tell you that this is also how we've evolved.

I think, got ahead in our thinking about how to use AI in healthcare in order to transform our industry.

No, no, it's totally exactly that.

In fact, so we see...

digital medicine, we define it in those two big pillars.

One would be, I mean, another term you could use is tech bio.

So those are the picks and shovels, the technologies that will help accelerate drug discovery, drug development.

And those are not products.

I mean, they are not clinical products.

Those are products you will use in order to develop better drugs, faster drugs, innovative drugs that you could not develop.

But the clients of those companies,